We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+55.49%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$355M
AUM Growth
+$139M
Cap. Flow
+$59.2M
Cap. Flow %
16.67%
Top 10 Hldgs %
32.72%
Holding
89
New
23
Increased
24
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$11.2M
2
EW icon
Edwards Lifesciences
EW
+$8.53M
3
DHR icon
Danaher
DHR
+$8.09M
4
ABBV icon
AbbVie
ABBV
+$6.6M
5
CTLT
CATALENT, INC.
CTLT
+$6.45M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.19M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.77M
4
ISRG icon
Intuitive Surgical
ISRG
+$4.49M
5
SDGR icon
Schrodinger
SDGR
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Technology 0.89%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
51
DELISTED
Akero Therapeutics
AKRO
$2.37M 0.67%
+95,000
New +$2.17M
KPTI icon
52
Karyopharm Therapeutics
KPTI
$46M
$2.29M 0.64%
8,053
-6,334
-44% -$1.87M
IRMD icon
53
iRadimed
IRMD
$1.12B
$2.2M 0.62%
94,717
-19,138
-17% -$411K
AUPH icon
54
Aurinia Pharmaceuticals
AUPH
$2.06B
$2.12M 0.6%
130,288
+10,000
+8% +$160K
NEPH icon
55
Nephros
NEPH
$47.4M
$2.11M 0.59%
251,366
– –
ATEC icon
56
Alphatec Holdings
ATEC
$1.49B
$2M 0.56%
426,599
+50,000
+13% +$221K
EIDX
57
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$1.96M 0.55%
41,085
-40,000
-49% -$1.86M
BHVN
58
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.83M 0.52%
+25,000
New +$1.33M
MSON
59
DELISTED
Misonix Inc
MSON
$1.76M 0.5%
129,997
-20,003
-13% -$245K
IMUX icon
60
Immunic
IMUX
$217M
$1.7M 0.48%
+14,000
New +$1.42M
MGTX icon
61
MeiraGTx Holdings
MGTX
$1.2B
$1.69M 0.48%
135,000
+10,000
+8% +$139K
APRE icon
62
Aprea Therapeutics
APRE
$8.46M
$1.55M 0.44%
2,002
+500
+33% +$328K
PVLA
63
Palvella Therapeutics
PVLA
$2.23B
$1.42M 0.4%
5,736
-500
-8% -$117K
SDGR icon
64
Schrodinger
SDGR
$1.39B
$1.37M 0.39%
15,000
-65,071
-81% -$3.79M
QDEL icon
65
QuidelOrtho
QDEL
$1.02B
$1.34M 0.38%
+6,000
New +$940K
GYRE icon
66
Gyre Therapeutics
GYRE
$706M
$1.26M 0.36%
28,698
– –
RAPT
67
DELISTED
RAPT Therapeutics
RAPT
$1.16M 0.33%
+5,000
New +$773K
ATXS
68
DELISTED
Astria Therapeutics
ATXS
$1M 0.28%
25,912
– –
MBIO icon
69
Mustang Bio
MBIO
$4.59M
$965K 0.27%
405
– –
MNKD icon
70
MannKind Corp
MNKD
$1.24B
$964K 0.27%
551,117
-350,000
-39% -$489K
CSTL icon
71
Castle Biosciences
CSTL
$960M
$942K 0.27%
+25,000
New +$854K
AMRN
72
Amarin Corp
AMRN
$297M
$873K 0.25%
6,306
+2,500
+66% +$344K
CDMO
73
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
$821K 0.23%
+125,000
New +$698K
SURF
74
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$820K 0.23%
+125,000
New +$451K
MRNA icon
75
Moderna
MRNA
$25.4B
$642K 0.18%
10,000
-65,000
-87% -$3.56M
1 2
3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Parkman Healthcare Partners held 89 positions worth $355M, up 64% from $216M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners deployed $59.2M of net new capital in Q2 2020, opening 23 new positions and adding to 24 existing holdings. Its largest new stake was Humana: 30,000 shares worth $11.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $7.1M trimmed.

  • Parkman Healthcare Partners's largest Q2 2020 buy was Humana: 30,000 shares worth $11.6M.
  • Parkman Healthcare Partners added most to GenMark Diagnostics, Inc in Q2 2020, an estimated $6.1M increase.
  • Parkman Healthcare Partners's biggest Q2 2020 reduction was Merck, cutting an estimated $7.1M.
  • Parkman Healthcare Partners fully exited Momenta Pharmaceuticals, Inc. in Q2 2020, selling an estimated $4.77M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $355M portfolio in Q2 2020.
  • Parkman Healthcare Partners opened 23 new positions and closed 10 in Q2 2020.
  • Parkman Healthcare Partners's portfolio value rose 64% quarter-over-quarter to $355M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2020, filed 13 Aug 2020.